The company recently announced results from two Phase 3 trials of AXS-05 for agitation. ACCORD-2, hit its main goal, but ...

In one study, the company’s drug eased the agitation for Alzheimer’s patients. In a different study, there wasn’t a ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

With two earlier trials meeting their primary endpoints, Axsome claimed it has the data to support a filing for FDA approval ...

University of Pittsburgh researchers uncovered a surprising link between Alzheimer's disease and herpes simplex virus-1 (HSV-1), suggesting that viral infections may play a role in the disease.

Axsome Therapeutics, Inc. (NASDAQ:AXSM) released data from ACCORD-2, ADVANCE-2, and long-term safety trials AXS-05 ...

Axsome Therapeutics shows strong revenue growth with promising pipeline drugs for migraine, fibromyalgia, and narcolepsy.

US CNS specialist Axsome Therapeutics yesterday announced the completion of its Phase III clinical program evaluating AXS-05 ...

H.C. Wainwright analyst Ram Selvaraju has reiterated their bullish stance on AXSM stock, giving a Buy rating yesterday.Don't Miss Our New ...

Axsome Therapeutics, Inc. has successfully completed its phase 3 clinical program for AXS-05 in treating Alzheimer’s disease agitation. The ACCORD-2 trial achieved the primary endpoint by ...

Shares of Axsome Therapeutics (AXSM) are under pressure on Monday after the company reported mixed results for a pair of studies of its ...